US 9,809,572 B2
Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds
Binhua Lv, Jiangsu (CN); Chengwei Li, Jiangsu (CN); Benwen Cao, Jiangsu (CN); and Xudong Pang, Jiangsu (CN)
Assigned to Suzhou Zelgen Biopharmaceuticals Co., Ltd., Jiangsu (CN)
Appl. No. 14/786,069
Filed by Suzhou Zelgen Biopharmaceuticals Co., Ltd., Jiangsu (CN)
PCT Filed Apr. 22, 2014, PCT No. PCT/CN2014/075958
§ 371(c)(1), (2) Date Feb. 16, 2016,
PCT Pub. No. WO2014/173291, PCT Pub. Date Oct. 30, 2014.
Claims priority of application No. 2013 1 0141192 (CN), filed on Apr. 22, 2013.
Prior Publication US 2016/0185753 A1, Jun. 30, 2016
Int. Cl. C07D 401/12 (2006.01); C07D 211/26 (2006.01); C07D 239/42 (2006.01)
CPC C07D 401/12 (2013.01) [C07D 211/26 (2013.01); C07D 239/42 (2013.01); C07B 2200/13 (2013.01)] 16 Claims
 
1. A deuterated diaminopyrimidine compound, or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof of formula (I):

OG Complex Work Unit Drawing
wherein:
R1a, R1b, R1c, R2a, R2b, R2c, R3, R4, R5, R6, R7, R9, R10, R11, R12, R13a, R13b, R13c, R14a, R14b, R14c, R15a, R15b, R15c, R16, R17a, R17b, R18a, R18b, R19a, R19b, R20a and R20b are independently hydrogen, deuterium or halogen;
R8 is halogen;
with the proviso that at least four of R1a, R1b, R1c, R2a, R2b, R2c, R3, R12, R13a, R13b, R13c, R14a, R14b, R14c, R19a, R19b, R20a and R20b are deuterium.